Annals of medicine and surgery (2012)Oct 13, 2026

New drug treatment for obesity: oral semaglutide for weight loss

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 14, 2026

Abstract

Oral semaglutide has been shown to produce clinically meaningful weight loss in adults with overweight or obesity, achieving significant improvements in metabolic health markers.

Oral semaglutide, when combined with lifestyle intervention, may lead to enhanced weight loss compared to lifestyle changes alone.
Improvements in physical function and cardiometabolic risk factors, including waist circumference and lipid levels, are associated with the use of oral semaglutide.
The oral formulation of semaglutide could improve patient accessibility and adherence compared to injectable therapies.
Future studies are needed to evaluate long-term efficacy, cardiovascular outcomes, and the comparative effectiveness of oral semaglutide against other treatment options.

Simplified

Obesity is a chronic, multifactorial disease characterized by excessive adiposity and associated with an increased risk of cardiovascular disease, type 2 diabetes, and reduced quality of life. Despite the widespread adoption of lifestyle interventions, long-term weight maintenance remains challenging, highlighting the need for effective pharmacologic therapies. Recent advances, including the US Food and Drug Administration approval of oral semaglutide, offer new opportunities for patient-centered obesity management. Evidence from the OASIS 1 and OASIS 4 trials demonstrates that oral semaglutide, combined with lifestyle intervention, produces clinically meaningful weight loss in adults with overweight or obesity without type 2 diabetes, while improving physical function and cardiometabolic risk markers, such as waist circumference, lipids, and inflammatory parameters. These trials further underscore the benefits of an oral formulation in improving accessibility and adherence compared with injectable therapies. Collectively, oral semaglutide represents a significant advancement in obesity pharmacotherapy, complementing lifestyle interventions and providing both metabolic and functional benefits. Future studies addressing long-term efficacy, cardiovascular outcomes, comparative effectiveness with other agents, and real-world implementation will be essential to fully define its role in comprehensive, individualized obesity care.

New drug treatment for obesity: oral semaglutide for weight loss

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief